98%
921
2 minutes
20
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique used to treat neuropathic orofacial pain (NOP). This study aimed to evaluate the efficacy and safety of rTMS in managing NOP and reducing health risks. A comprehensive literature search was conducted in various databases, including PubMed, Physiotherapy Evidence Database (PEDro), the Cochrane Library, Web of Science, Embase and Clinical Trials.gov. Thirteen relevant articles were identified and assessed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Risk of Bias assessment tool. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was utilized to evaluate the evidence rating for the studies. The analysis of the thirteen randomized controlled trials, involving 355 eligible patients, demonstrated moderate evidence supporting the significant effect of rTMS in reducing pain intensity (Mean Difference (MD): -1.01, 95% Confidence Interval (CI) -2.39 to -1.48, < 0.001) and improving the quality of life (QOL) based on various instruments (MD: -9.23, 95% CI -11.91 to -6.54, < 0.001; MD: -2.1, 95% CI -3.74 to -0.45, < 0.05). Patients also reported favorable improvements in global impression (MD: -0.54, 95% CI -1.02 to -0.07, < 0.05) and sensory status (Standardized Mean Difference (SMD): -1.30, 95% CI -1.74 to -0.87, < 0.001). However, there were no significant improvements in sleep quality (MD: -1.72, 95% CI -4.13 to 0.68, > 0.05) or psychological status ( > 0.05). Overall, the study demonstrated that rTMS is an effective and safe way to reduce pain, improve QOL, enhance sensory status, and create a positive clinical impression in patients with NOP. Further research is needed to investigate the effects of rTMS on sleep and psychological well-being in individuals with NOP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810666 | PMC |
http://dx.doi.org/10.22514/jofph.2024.013 | DOI Listing |
Br J Health Psychol
September 2025
Manchester Centre for Health Psychology, School of Health Sciences, University of Manchester, Manchester, UK.
Objective: This study applied the Theoretical Domains Framework (TDF) to explore the barriers and enablers to optimizing post-operative pain management and supporting safe opioid use from the perspectives of both patients and health care professionals, applying the Theoretical Domains Framework (TDF).
Design: Experience-based co-design (EBCD) qualitative study.
Methods: In the initial phase of the EBCD approach, focus groups were conducted comprising 20 participants, including 8 patients and 12 health care professionals involved in post-operative care.
Immunotherapy
September 2025
aGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rev Med Liege
September 2025
Service de Gastroentérologie, CHU Liège, Belgique.
Bariatric endoscopy is an increasingly recognized alternative to surgery for obesity treatment. Recent guidelines from leading medical societies (IFSO, ASMBS, ASGE, ESGE) have included endoscopic sleeve gastroplasty (ESG) and the intragastric balloon (IGB) in their recommendations. These procedures are indicated for patients with a body mass index (BMI) between 27 and 40 kg/m² who cannot or do not wish to undergo surgery.
View Article and Find Full Text PDFCardiol Young
September 2025
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
The Occlutech Atrial Flow Regulator is a self-expandable double-disc nitinol device with a central fenestration designed to create a calibrated communication across the interatrial septum. It has been used in adult patients with heart failure and pulmonary hypertension. Its use in the paediatric population or adults with CHD has been published in several case reports and case series.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
September 2025
City St George's University of London, London, UK.
Introduction: Etripamil is a fast-acting intranasally self-administered calcium-channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE-303 is an open-label, single-arm study that evaluated etripamil for multiple, at-home PSVT episodes, without test dose before first use.
View Article and Find Full Text PDF